Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)
Completed · Phase 2
Conditions studied: Chronic Hepatitis C
In brief
Open label phase 2a study of two week treatment with CDI-31244 and sofosbuvir and veltapasvir followed by four week treatment of sofosbuvir and velpatasvir in individuals with chronic hepatitis C (HCV) genotype 1 (GT1) infection
Key facts
- Study ID
- NCT03501550
- Run by
- Cocrystal Pharma, Inc.
- People needed
- 12
- Starts
- 2018-06-26
- Expected to finish
- 2019-06-07
- Last updated by the study team
- 2021-04-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Institute of Human Virology University of Maryland — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.